Provider Briefing: Janumet Availability in 2026

As a prescriber managing patients with type 2 diabetes, you've likely fielded questions about Janumet (Sitagliptin/Metformin) availability. While not formally in shortage, Janumet's single-manufacturer status and brand-only pricing create access challenges that directly affect patient adherence and outcomes.

This briefing covers the current supply picture, prescribing implications, cost considerations, and practical tools to help your patients maintain continuity of care.

Timeline: How We Got Here

Janumet was FDA-approved in 2007 as a fixed-dose combination of Sitagliptin (a DPP-4 inhibitor) and Metformin Hydrochloride (a biguanide). Since then, it has become one of the most widely prescribed diabetes combination therapies in the United States.

Key milestones to note:

• 2007: FDA approval of Janumet (immediate-release)
• 2012: FDA approval of Janumet XR (extended-release)
• 2022-2024: GLP-1 agonist demand surge puts pressure on entire diabetes drug supply chain
• November 24, 2026: Key Sitagliptin patent expiration — generic competition expected shortly after

The upcoming patent cliff is particularly relevant for prescribing decisions and formulary planning in your practice.

Prescribing Implications

Current Supply Status

Janumet is not listed on the FDA Drug Shortage Database as of early 2026. However, localized stock-outs are reported by patients, particularly at chain pharmacies in some regions. These "spot shortages" stem from:

• Single-source manufacturing (Merck is the sole producer)
• Pharmacy stocking decisions favoring higher-volume or lower-cost generics
• Distributor allocation during high-demand periods

Formulary Considerations

Janumet is typically classified as a Tier 3 (preferred brand) on most commercial and Medicare Part D formularies. However, prescribers should be aware that:

• Some plans require step therapy — patients must trial Metformin alone before accessing Janumet
• Prior authorization may be required by certain payers
• Formulary tier placement varies by plan year, and some plans may have moved Janumet to a higher tier
• As generic competition approaches, expect formulary shifts

Renal Dosing Reminders

Due to the Metformin component, Janumet carries important renal considerations:

• eGFR ≥45 mL/min/1.73m²: No dose adjustment needed, though monitoring is recommended
• eGFR 30-45 mL/min/1.73m²: Not recommended to initiate; may continue with monitoring if already established
• eGFR <30 mL/min/1.73m²: Contraindicated
• Temporarily discontinue before iodinated contrast procedures

Availability Picture

In practice, Janumet availability in 2026 looks like this:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Generally available but may experience periodic stock-outs of specific strengths
• Independent pharmacies: Often have more flexible ordering and may source from multiple wholesalers
• Mail-order pharmacies: Typically maintain adequate supply for 90-day fills
• Hospital outpatient pharmacies: Usually well-stocked

When patients report difficulty finding Janumet, direct them to Medfinder for Providers — a free tool that helps locate pharmacies with current stock.

Cost and Access Considerations

Cost remains a significant barrier to adherence:

• Average cash price: $600-$750/month (60 tablets)
• Merck savings card: Reduces copay to as low as $5/month for commercially insured patients (not valid for government insurance)
• Medicare patients: Typically Tier 3 copay; no manufacturer card eligibility
• Merck Patient Assistance Program (merckhelps.com): Provides Janumet free to eligible uninsured/underinsured patients

For patients struggling with cost, a detailed resource is available at our provider's guide to helping patients save on Janumet.

Generic Timeline

The Sitagliptin patent expires November 24, 2026. Several generic manufacturers have filed ANDAs. Once approved:

• Generic Sitagliptin/Metformin could be priced at $50-$150/month (an 80-85% reduction)
• Multiple manufacturers should improve supply reliability
• Formulary tiers will likely shift generics to Tier 1 or 2

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps you and your staff quickly identify pharmacies with Janumet in stock, saving time on prior authorizations and prescription transfers. It's free and requires no account to use.

Prescribing Alternatives

When Janumet is unavailable or cost-prohibitive, consider these therapeutic alternatives:

• Jentadueto (Linagliptin/Metformin): No renal dose adjustment needed for the Linagliptin component — advantageous for patients with mild-moderate CKD
• Kombiglyze XR (Saxagliptin/Metformin ER): Once-daily dosing may improve adherence; note SAVOR-TIMI 53 heart failure signal with Saxagliptin
• Kazano (Alogliptin/Metformin): Twice-daily dosing; another DPP-4/Metformin combination option
• Separate prescriptions: Januvia (Sitagliptin) + generic Metformin — allows independent dose titration

For more on alternatives, see our patient-facing article on alternatives to Janumet.

Patient Education Resources

Direct patients to these Medfinder resources:

• What is Janumet? Uses, dosage, and what you need to know
• Janumet side effects: What to expect and when to call your doctor
• Janumet drug interactions: What to avoid
• How to save money on Janumet

Looking Ahead

The landscape for Janumet prescribing is poised to change significantly in late 2026 and into 2027:

• Generic entry should dramatically improve both cost and availability
• Formulary shifts will likely favor generic Sitagliptin/Metformin over brand Janumet
• Biosimilar and new-class competition in the broader diabetes market continues to expand treatment options

In the meantime, proactive communication with patients about availability, cost-saving strategies, and backup plans will help maintain adherence and glycemic control.

Final Thoughts

Janumet remains an effective and well-tolerated option for type 2 diabetes management. While current access challenges are real, they are manageable with the right tools and communication strategies. Utilize Medfinder for Providers to streamline pharmacy searches, familiarize your staff with Merck's savings programs, and keep generic timelines on your radar for formulary planning.

For a patient-focused perspective, see our Janumet shortage update for patients.